What started as a treatment for type 2 diabetes has rapidly evolved into a platform therapy influencing obesity, cardiovascular disease, fatty liver disease, neurodegeneration, inflammation, and potentially oncology
Zfp423 expression identifies committed preadipocytes and localizes to adipose endothelial and perivascular cells
Apr 29, 2025, 08:00 ET All doses of FDA-approved Wegovy , the most widely prescribed and studied GLP-1 for weight loss, are now accessible to patients of select telehealth providers via simplified pathway to NovoCare Pharmacy Providers include Hims & Hers Health, Inc., LifeMD, and Ro Wegovy is in full supply, and patients in the US can access authentic, FDA-approved Wegovy in a high-quality premium pen for $499 per month Novo Nordisk continues to explore new pathways to conveniently and affordably connect people living with obesity to Wegovy PLAINSBORO, N.J., April 29, 2025 /PRNewswire/ -- Today, Novo Nordisk announced it is expanding patient access to Wegovy (semaglutide) injection 2.4 mg by enabling select telehealth providers to work directly through NovoCare Pharmacy to offer a simplified pathway for self-paying patients seeking access to authentic, FDA-approved Wegovy
Neuroprotective Benefits Reduced risk of neurodegenerative diseases: Semaglutide may have neuroprotective effects, which can help reduce the risk of neurodegenerative diseases such as Alzheimers and Parkinsons
